Chemotherapy-induced lung disease.

The lung has significant susceptibility to injury from a variety of chemotherapeutic agents. The clinician must be familiar with classic chemotherapeutic agents with well-described pulmonary toxicities and must also be vigilant about a host of new agents that may exert adverse effects on lung function. The diagnosis of chemotherapy-associated lung disease remains an exclusionary process, particularly with respect to considering usual and atypical infections, as well as recurrence of the underlying neoplastic process in these immune compromised patients. In many instances, chemotherapy-associated lung disease may respond to withdrawal of the offending agent and to the judicious application of corticosteroid therapy.

[1]  R. Matthay,et al.  Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. , 1986, The American review of respiratory disease.

[2]  E. Rosenow,et al.  Oxygen-exacerbated bleomycin pulmonary toxicity. , 1991, Mayo Clinic proceedings.

[3]  J. Husband,et al.  Bleomycin-related lung damage: CT evidence. , 1985, Radiology.

[4]  P. Hilliquin,et al.  Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. , 1996, British journal of rheumatology.

[5]  P. Camus,et al.  La pneumopathie du busulfan. , 1987 .

[6]  E. Rosenow,et al.  Drug-induced pulmonary disease. An update. , 1992, Chest.

[7]  K. Lote,et al.  Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review. , 1990, Acta oncologica.

[8]  M. Fukuoka,et al.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Y. Ahn,et al.  Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Meera Patel,et al.  Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside , 2001, European journal of haematology.

[11]  J. Myers,et al.  Lung toxicity associated with cyclophosphamide use. Two distinct patterns. , 1996, American journal of respiratory and critical care medicine.

[12]  E. Bini,et al.  Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. , 1999, Mayo Clinic proceedings.

[13]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Naidich,et al.  Interferon-induced sarcoidosis. , 2003, Journal of computer assisted tomography.

[15]  E. Rosenow.  Chemotherapeutic Drug-Induced Pulmonary Disease , 1980 .

[16]  R. Cairoli,et al.  Detection by polymerase chain reaction of BCR/ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation. , 1995, European journal of cancer.

[17]  Kresina Tf,et al.  Immunology of articular cartilage. , 1987 .

[18]  G. Bjarnason,et al.  Irinotecan-associated pulmonary toxicity. , 2000, Anti-cancer drugs.

[19]  R. Kradin,et al.  Alterations in pulmonary function in cancer patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2. , 1990, The American review of respiratory disease.

[20]  J. Husband,et al.  Computed tomography of pulmonary bleomycin toxicity. , 1990, Seminars in ultrasound, CT, and MR.

[21]  S. Spencer,et al.  Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. , 1999, Seminars in radiation oncology.

[22]  C. Chan,et al.  Bleomycin-induced pulmonary function abnormalities. , 1992, Chest.

[23]  P. Tarassoff,et al.  950 Dyspnoea with gemcitabine is commonly seen, often disease related, transient, and rarely severe , 1995 .

[24]  D. S. Klein,et al.  Pulmonary toxicity of antineoplastic agents: Anaesthetic and postoperative implications , 1983, Canadian Anaesthetists' Society journal.

[25]  B. Crestani,et al.  Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[26]  S. Prindiville,et al.  Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. , 1998, American journal of respiratory and critical care medicine.

[27]  W. Webb,et al.  Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients. , 1991, AJR. American journal of roentgenology.

[28]  D. Hocking,et al.  Mechanisms of pulmonary edema induced by tumor necrosis factor-alpha. , 1990, Circulation research.

[29]  J. McCravey,et al.  Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. , 1985, Archives of internal medicine.

[30]  T. Vial,et al.  Clinical Toxicity of Cytokines Used As Haemopoietic Growth Factors , 1995, Drug safety.

[31]  R. Figlin,et al.  Pulmonary toxicity of recombinant human tumor necrosis factor. , 1989, Chest.

[32]  E. Conant,et al.  Pulmonary edema as a complication of interleukin-2 therapy. , 1989, AJR. American journal of roentgenology.

[33]  F. Askin,et al.  Nodular form of bleomycin‐related pulmonary injury in patients with osteogenic sarcoma , 1989, Cancer.

[34]  J. Szer,et al.  The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation , 1991, British journal of haematology.

[35]  H. Sluiter,et al.  Natural course of bleomycin-induced pneumonitis. A follow-up study. , 1987, The American review of respiratory disease.

[36]  A. Borczuk,et al.  Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C , 2002, American Journal of Gastroenterology.

[37]  John F. Murray,et al.  Textbook of Respiratory Medicine , 1988 .

[38]  J. Wiley,et al.  Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. , 1995, Leukemia.

[39]  R. Warrell,et al.  The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.

[40]  J. Byrd,et al.  Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. , 2002, Chest.

[41]  D. Linette,et al.  Mitomycin-Induced Pulmonary Toxicity: Case Report and Review of the Literature , 1992, The Annals of pharmacotherapy.

[42]  R. Schein,et al.  Severe Pulmonary Toxicity in a Patient Treated With Gemcitabine , 2002, American journal of clinical oncology.

[43]  M. Dimopoulos,et al.  A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin , 2002, Cancer.

[44]  G. Carlon,et al.  Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. , 1978, British medical journal.

[45]  D. Clegg,et al.  Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. , 1987, Seminars in arthritis and rheumatism.

[46]  V. Shannon,et al.  PULMONARY COMPLICATIONS OF CANCER THERAPY , 1998 .

[47]  B. Mehrotra,et al.  Gemcitabine-Induced Pulmonary Toxicity: Case Report and Review of the Literature , 2002, American journal of clinical oncology.

[48]  Robert Luke,et al.  Harrison's Online , 1999, J. Educ. Technol. Soc..

[49]  J. Aymard,et al.  A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia a peculiar pathologic aspect of busulfan lung? , 1984, Cancer.

[50]  B. Crestani,et al.  Acute Respiratory Failure after Interferon-γ Therapy of End-Stage Pulmonary Fibrosis , 2003 .

[51]  D. White,et al.  Bleomycin-induced pulmonary toxicity. , 1990, Clinics in chest medicine.

[52]  D. Nelson,et al.  Pulmonary toxicity of carmustine in patients treated for malignant glioma. , 1986, Cancer treatment reports.

[53]  K. Hoelzer,et al.  Vinblastine-Associated Pulmonary Toxicity in Patients Receiving Combination Therapy with Mitomycin and Cisplatin , 1986, Drug intelligence & clinical pharmacy.

[54]  R. Comis,et al.  The pulmonary toxicity of antineoplastic agents. , 1982, Seminars in oncology.

[55]  C. Yee,et al.  Fatal pulmonary failure complicating high‐dose cytosine arabinoside therapy in acute leukemia , 1990, Cancer.

[56]  J. J. Johnson,et al.  Toxicity of methotrexate in rheumatoid arthritis. , 1987, The Journal of rheumatology.

[57]  J. Parish,et al.  Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation. , 2003, Mayo Clinic proceedings.

[58]  R. Golding,et al.  Prospective study on the dose relationship of mitomycin C–induced interstitial pneumonitis , 1987, Cancer.

[59]  A. Woodcock,et al.  Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. , 1990, The New England journal of medicine.

[60]  R. Makuch,et al.  Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Bartolucci,et al.  Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). , 1979, Annals of internal medicine.

[62]  J. Myers.  Pathology of drug-induced lung disease , 1997 .

[63]  R. Speichb,et al.  Gemcitabine-related pulmonary toxicity , 2002 .

[64]  W. Wilmanns,et al.  Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia , 1988, Medical oncology and tumor pharmacotherapy.

[65]  R. Pazdur,et al.  FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.

[66]  E. Rosenow,et al.  Drug-induced pulmonary disease. , 1995, Disease-a-month : DM.

[67]  E. Mark,et al.  Case 37-1990 , 1990 .

[68]  E. Shaw,et al.  Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell lung cancer. , 1995, International journal of radiation oncology, biology, physics.

[69]  H. Tran,et al.  Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[70]  Matthay Ra,et al.  Pulmonary effects of cytotoxic agents other than bleomycin. , 1990 .

[71]  J. Guerin,et al.  [Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases]. , 1998, Revue des maladies respiratoires.

[72]  A. Bateman,et al.  Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  G. Kalemkerian,et al.  Etoposide-induced pulmonary toxicity. , 1999, Lung cancer.

[74]  M. Luna,et al.  Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. , 1980, Human pathology.

[75]  C. Belani,et al.  Pulmonary infiltrates following administration of paclitaxel. , 1996, Chest.

[76]  K. Sueishi,et al.  Pulmonary Alveolar Proteinosis and Disseminated Atypical Mycobacteriosis in a Patient with Busulfan Lung , 1990, Acta pathologica japonica.

[77]  F. Massin,et al.  [Nitrosourea-induced lung diseases]. , 1992, Revue des maladies respiratoires.

[78]  R. Sheldon,et al.  A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy‐treated patients with adenocarcinoma , 1986, Cancer.

[79]  J. Austin,et al.  Nodular bleomycin toxicity. , 1989, American journal of clinical pathology.

[80]  R. Cooke,et al.  Busulphan lung , 1968, Thorax.